Evidence map›Paper›PMID 38959399›Full record

ArticleBlood advances2024

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.

Joana de Matos Rodrigues, Lavanya Lokhande, Lina M Olsson, May Hassan, Angelica Johansson, Anna Janská, Darshan Kumar, Lina Schmidt, Anna Nikkarinen, Peter Hollander and 5 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. The Novel Immunocompetent Eµ-SOX11CCND1 Mouse Model Phenotypically and Molecularly Resembles Human Mantle Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joana de Matos RodriguesDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0003-1806-331X
Lavanya LokhandeDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0002-0045-8076
Lina M OlssonDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0002-1359-0295
May HassanDepartment of Immunotechnology, Lund University, Lund, Sweden.
Angelica JohanssonDepartment of Immunotechnology, Lund University, Lund, Sweden.
Anna JanskáDepartment of Immunotechnology, Lund University, Lund, Sweden.
Darshan KumarAiforia Technologies Plc, Helsinki, Finland.ORCID 0000-0001-5371-1779
Lina SchmidtDepartment of Immunotechnology, Lund University, Lund, Sweden.
Anna NikkarinenDepartment of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.ORCID 0009-0001-1451-0699
Peter HollanderDepartment of Immunology, Genetics and Pathology, Clinical and Experimental Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-0226-5681
Ingrid GlimeliusDepartment of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-6158-3041
Anna PorwitDivision of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Anna Sandstrom GerdtssonDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0003-1932-0365
Mats JerkemanDivision of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Sara EkDepartment of Immunotechnology, Lund University, Lund, Sweden.ORCID 0000-0002-1388-4912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMantle cell lymphoma (MCL) is dependent on a supportive tumor immune microenvironment (TIME) in which infiltration of CD163+ macrophages has a negative prognostic impact. This study explores how abundance and spatial localization of CD163+ cells are associated with the biology of MCL, using spatial multiomic investigations of tumor and infiltrating CD163+ and CD3+ cells. A total of 63 proteins were measured using GeoMx digital spatial profiling in tissue microarrays from 100 diagnostic MCL tissues. Regions of interest were selected in tumor-rich and tumor-sparse tissue regions. Molecular profiling of CD163+ macrophages, CD20+ MCL cells, and CD3+ T-cells was performed. To validate protein profiles, 1811 messenger RNAs were measured in CD20+ cells and 2 subsets of T cells. Image analysis was used to extract the phenotype and position of each targeted cell, thereby allowing the exploration of cell frequencies and cellular neighborhoods. Proteomic investigations revealed that CD163+ cells modulate their immune profile depending on their localization and that the immune inhibitory molecules, V-domain immunoglobulin suppressor of T-cell activation and B7 homolog 3, have higher expression in tumor-sparse than in tumor-rich tissue regions and that targeting should be explored. We showed that MCL tissues with more abundant infiltration of CD163+ cells have a higher proteomic and transcriptional expression of key components of the MAPK pathway. Thus, the MAPK pathway may be a feasible therapeutic target in patients with MCL with CD163+ cell infiltration. We further showed the independent and combined prognostic values of CD11c and CD163 beyond established risk factors.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticLymphoma, Mantle-CellMacrophagesReceptors, Cell SurfaceTumor MicroenvironmentCD163 AntigenHumansSignal TransductionAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell Surface

Identifiers

PMID38959399
PMCPMC11375268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.